ConductScience.org, home

Paper34066908

Intratumoral (Poly-ICLC) Therapy for Dogs with Advanced Cancers: First Report on Clinical Effectiveness, Quality of Life, and Adverse Events.

Voges ARN and 6 others. Cancers (Basel), 2021. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Intratumoral (Poly-ICLC) Therapy for Dogs with Advanced Cancers: First Report on Clinical Effectiveness, Quality of Life, and Adverse Events. Papers, record 34066908. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34066908

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Intratumoral (Poly-ICLC) Therapy for Dogs with Advanced Cancers: First Report on Clinical Effectiveness, Quality of Life, and Adverse Events.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2021
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Relative citation ratio, by iCite
0.08
iCite
Revised in PubMed
2021-06-05
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Voges ARNAlessandra Rinah Nogueira
2Ubukata RRodrigo
3Yazbek KVBKarina Velloso Braga
4Caballero OLOtávia Luisa
5Salazar AMAndres Mario
6Massoco COCristina de Oliveira
7Dagli MLZMaria Lucia Zaidanhttps://orcid.org/0000-0001-7031-6711

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
PEI 0069/15Financiadora de Estudos e ProjetosPubMed

Source PubMed

Download CSV of grants

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130962585Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination.Nat Med2019https://conductscience.org/library/papers/30962585PubMed
2402107Interferon induction in cynomolgus and rhesus monkey after repeated doses of a modified polyriboinosinic-polyribocytidylic acid complex.Antimicrob Agents Chemother1977https://conductscience.org/library/papers/402107PubMed
322065672Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans.J Exp Med2011https://conductscience.org/library/papers/22065672PubMed
428848723
A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect.
J Hepatocell Carcinoma2017https://conductscience.org/library/papers/28848723PubMed
528678778An immunogenic personal neoantigen vaccine for patients with melanoma.Nature2017https://conductscience.org/library/papers/28678778PubMed
630753611Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.Neuro Oncol2019https://conductscience.org/library/papers/30753611PubMed
78727138Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study.Neurosurgery1996https://conductscience.org/library/papers/8727138PubMed
818262679TLR3: interferon induction by double-stranded RNA including poly(I:C).Adv Drug Deliv Rev2008https://conductscience.org/library/papers/18262679PubMed
930568303Actively personalized vaccination trial for newly diagnosed glioblastoma.Nature2019https://conductscience.org/library/papers/30568303PubMed
1026545847Cancer immunotherapy in veterinary medicine: Current options and new developments.Vet J2016https://conductscience.org/library/papers/26545847PubMed
116163381Minimal interferon induction in dogs, using a modified polyriboinosinic-polyribocytidylic acid complex.Am J Vet Res1980https://conductscience.org/library/papers/6163381PubMed
1230500529Putting the Immunologic Brakes on Cancer.Cell2018https://conductscience.org/library/papers/30500529PubMed
1329224713Veterinary Oncology Immunotherapies.Vet Clin North Am Small Anim Pract2018https://conductscience.org/library/papers/29224713PubMed
1432958686Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration.J Immunother Cancer2020https://conductscience.org/library/papers/32958686PubMed
1529950349Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.Clin Cancer Res2018https://conductscience.org/library/papers/29950349PubMed
1618797818A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).J Neurooncol2009https://conductscience.org/library/papers/18797818PubMed
1733011064Poly-ICLC, a multi-functional immune modulator for treating cancer.Semin Immunol2020https://conductscience.org/library/papers/33011064PubMed
1824309609Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors.J Pediatr Hematol Oncol2014https://conductscience.org/library/papers/24309609PubMed
1919615405Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate immunity.Pharmacol Ther2009https://conductscience.org/library/papers/19615405PubMed
2026056372Comparative oncology: what dogs and other species can teach us about humans with cancer.Philos Trans R Soc Lond B Biol Sci2015https://conductscience.org/library/papers/26056372PubMed

See all 37 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
36831676Translational and Comparative Research on Innovative Anti-Cancer Therapies.Cancers (Basel)2023https://conductscience.org/library/papers/36831676

Source PubMed

Download CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EIF2AK25610PubTator's text mininghttps://conductscience.org/library/genes/5610NCBI Gene
IFIH164135PubTator's text mininghttps://conductscience.org/library/genes/64135NCBI Gene
IFNA13439PubTator's text mininghttps://conductscience.org/library/genes/3439NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
RET5979PubTator's text mininghttps://conductscience.org/library/genes/5979NCBI Gene
RIGI23586PubTator's text mininghttps://conductscience.org/library/genes/23586NCBI Gene
TLR37098PubTator's text mininghttps://conductscience.org/library/genes/7098NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34066908

GET https://conductscience.org/api/papers/v1/34066908/references?page=2